Convergence Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Convergence Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,199	Closed	-$674K	–	293
2025 Q3	$674K	Buy	+1,199	New	+$678K	0.15%	187
2024 Q3	–	Sell	-191	Closed	-$201K	–	280
2024 Q2	$201K	Buy	+191	New	+$185K	0.06%	237
2023 Q4	–	Sell	-298	Closed	-$245K	–	206
2023 Q3	$245K	Buy	+298	New	+$234K	0.14%	129
2022 Q3	–	Sell	-627	Closed	-$371K	–	242
2022 Q2	$371K	Sell	627 -91	-13%	-$59.2K	0.22%	105
2022 Q1	$501K	Buy	718 +98	+16%	+$62K	0.26%	98
2021 Q4	$392K	Buy	+620	New	+$381K	0.2%	117
2018 Q2	–	Sell	-119	Closed	-$41K	–	762
2018 Q1	$41K	Buy	+119	New	+$41.4K	0.01%	470

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Convergence Investment Partners's REGN Position: Q4 2025 in Review

Convergence Investment Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 1,199 shares — an estimated $674K sold.

Convergence Investment Partners first reported a position in REGN in Q1 2018 and held it in 7 quarters. The position peaked at $674K in Q3 2025. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Convergence Investment Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Convergence Investment Partners sold 1,199 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $674K.
Convergence Investment Partners first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 7 quarters.
Convergence Investment Partners's Regeneron Pharmaceuticals position peaked at $674K in Q3 2025.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Convergence Investment Partners's 13F filing for Q4 2025, filed 5 Feb 2026.